ShanghaiMay 27, 2026 /PRNewswire/ — Insilico Medicine (3696.HK), a generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation Models (“HLFM”), a newly established entity under Human Longevity, today announced a multi-million dollar strategic collaboration to jointly develop the industry’s first large-scale AI foundation models dedicated to human longevity science.
As global demographic shifts reshape labor markets and consumer demand, longevity has transcended pure scientific inquiry to become a notable global economic strategy. According to a recent analysis by UBS, the global longevity economy has reached $5.3 trillion and is projected to surge to $8 trillion by 2030. As a core growth driver in this trillion-dollar arena, AI-powered longevity research is emerging as a fundamental enabler. By deeply modeling aging biology, accurately predicting disease risks, and rapidly advancing the development of preventive interventions, it seeks to fundamentally explore the boundaries of human healthspan.
Under this collaboration, Insilico Medicine and HLFM will jointly develop super-intelligent AI foundation models to decode the mechanisms of aging biology and enable predictive diagnostics and therapeutics. Within this framework, Insilico Medicine will leverage its expertise in multimodal foundation model development and deep learning system construction. Utilizing the advanced MMAI Gym framework for model training and evaluation, Insilico will systematically provide model architecture design, benchmarking, training guidelines, and core computational algorithms, serving as the technical backbone for the jointly developed models.
Insilico Medicine and Human Longevity Partner to Develop Industry’s First AI Foundation Models for Longevity Science
HLFM will integrate these tools and capabilities with Human Longevity’s proprietary, de-identified multi-omics and clinical datasets to further train and refine advanced multimodal AI models. With over a decade of research, Human Longevity has built one of the world’s most comprehensive integrated datasets, encompassing genomics, imaging, and longitudinal health records from thousands of individuals. By leveraging this vast data repository, HLFM will support the cognitive training of the foundation models, enabling the system to detect, diagnose, and manage user health conditions with clinical-grade precision.
By combining advanced algorithms with deep biological insights, the jointly developed foundation models are expected to be commercialized and drive breakthroughs in areas including: early detection of aging-related diseases, predictive health risk modeling, AI-driven discovery of innovative longevity drugs, and personalized interventions. These advancements will further shift the global healthcare paradigm from reactive disease treatment to proactive longevity science, playing a pivotal role in the future of life and health management.
Dr. Alex Zhavoronkov, Founder, CEO, and Chief Business Officer of Insilico Medicine, stated: “By combining Insilico’s expertise in multimodal large model development with HLFM’s unique longitudinal datasets, and conducting high-standard model training and benchmark evaluation within the advanced MMAI Gym framework, we aim to build a ‘super-intelligent’ system capable of decoding the most complex mechanisms of aging biology. This collaboration is not just about creating a predictive engine for human lifespan, but more importantly, developing AI foundation models that can identify age-related risks with high precision and accelerate longevity drug discovery.”
Dr. Wei-Wu He, Executive Chairman of Human Longevity, said: “Human Longevity was founded with the vision of fundamentally transforming medicine by leveraging large-scale biological data combined with artificial intelligence. By facilitating this collaboration between HLFM and Insilico Medicine, we are taking a critical step toward creating foundation models for human health and longevity. This will help predict complex diseases earlier and guide interventions to extend healthspan.”
Since its inception, longevity science has been a core component of Insilico Medicine’s mission. As early as 2015 at the NVIDIA GTC conference, Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, sparked widespread attention in the tech community with the question: “Can NVIDIA Cure Aging?” Recently, Insilico announced the establishment of the industry’s first Longevity Committee, composed of renowned scientists and chaired by Dr. Andrew Adams, Vice President of the Molecular Discovery Group at Eli Lilly, aimed at accelerating AI-driven anti-aging drug development. To date, Insilico scientists have published over 50 papers related to aging and longevity research, covering areas such as aging biomarkers, therapeutic targets with the potential to simultaneously intervene in aging and disease, and corresponding treatment modalities.